))
Drafting the Future: Unpacking the FDA's Clinical Trial Diversity Action Plan
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on September 25, 2024 14:55 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 428465626 series 2916794
Konten disediakan oleh Hogan Lovells. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Hogan Lovells atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
In the third part of our clinical trial diversity series, Deborah Cho, Stephanie Agu, and Ashley Grey dissect FDA's new draft guidance on Diversity Action Plans for clinical trials, released on June 28, 2024. Discover what this pivotal document means for clinical trial design and conduct, and its implications for drug and biologic sponsors. Tune in for an insightful discussion on the future of clinical trials and FDA recommendations to ensure diverse participant inclusion.
You can find additional thought leadership and information regarding digital health on Engage.
If you are interested in more information about Life Sciences and Health Care, follow us via LinkedIn and Twitter.
52 episode
Bagikan
